Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 18.41
CDXS's Cash to Debt is ranked lower than
56% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. CDXS: 18.41 )
Ranked among companies with meaningful Cash to Debt only.
CDXS' s Cash to Debt Range Over the Past 10 Years
Min: 2.71  Med: 10000.00 Max: No Debt
Current: 18.41
Equity to Asset 0.41
CDXS's Equity to Asset is ranked lower than
78% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. CDXS: 0.41 )
Ranked among companies with meaningful Equity to Asset only.
CDXS' s Equity to Asset Range Over the Past 10 Years
Min: -1.82  Med: 0.70 Max: 0.79
Current: 0.41
-1.82
0.79
Interest Coverage N/A
CDXS's Interest Coverage is ranked higher than
50% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CDXS: N/A )
Ranked among companies with meaningful Interest Coverage only.
CDXS' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: 9999.50 Max: 9999.99
Current: N/A
N/A
9999.99
F-Score: 5
Z-Score: -5.94
M-Score: -3.98
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -21.45
CDXS's Operating margin (%) is ranked higher than
61% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -72.99 vs. CDXS: -21.45 )
Ranked among companies with meaningful Operating margin (%) only.
CDXS' s Operating margin (%) Range Over the Past 10 Years
Min: -155.16  Med: -54.13 Max: -6.65
Current: -21.45
-155.16
-6.65
Net-margin (%) -20.91
CDXS's Net-margin (%) is ranked higher than
61% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -74.36 vs. CDXS: -20.91 )
Ranked among companies with meaningful Net-margin (%) only.
CDXS' s Net-margin (%) Range Over the Past 10 Years
Min: -153.96  Med: -54.01 Max: -7.97
Current: -20.91
-153.96
-7.97
ROE (%) -44.51
CDXS's ROE (%) is ranked lower than
60% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. CDXS: -44.51 )
Ranked among companies with meaningful ROE (%) only.
CDXS' s ROE (%) Range Over the Past 10 Years
Min: -68.88  Med: -45.17 Max: -15.76
Current: -44.51
-68.88
-15.76
ROA (%) -21.95
CDXS's ROA (%) is ranked higher than
55% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. CDXS: -21.95 )
Ranked among companies with meaningful ROA (%) only.
CDXS' s ROA (%) Range Over the Past 10 Years
Min: -52.02  Med: -35.66 Max: -7.11
Current: -21.95
-52.02
-7.11
ROC (Joel Greenblatt) (%) -257.74
CDXS's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. CDXS: -257.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CDXS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -472.46  Med: -307.23 Max: -32.34
Current: -257.74
-472.46
-32.34
Revenue Growth (3Y)(%) -35.70
CDXS's Revenue Growth (3Y)(%) is ranked lower than
80% of the 491 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. CDXS: -35.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CDXS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -21.15 Max: -8
Current: -35.7
EBITDA Growth (3Y)(%) 40.60
CDXS's EBITDA Growth (3Y)(%) is ranked higher than
88% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -0.70 vs. CDXS: 40.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CDXS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 40.6
Current: 40.6
0
40.6
EPS Growth (3Y)(%) 2.50
CDXS's EPS Growth (3Y)(%) is ranked higher than
60% of the 499 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. CDXS: 2.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CDXS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 1.25 Max: 46
Current: 2.5
0
46
» CDXS's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-11)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

CDXS Guru Trades in Q2 2015

Jim Simons 654,200 sh (+41.63%)
» More
Q3 2015

CDXS Guru Trades in Q3 2015

Jim Simons 727,300 sh (+11.17%)
» More
Q4 2015

CDXS Guru Trades in Q4 2015

Jim Simons 753,100 sh (+3.55%)
» More
Q1 2016

CDXS Guru Trades in Q1 2016

Jim Simons 807,000 sh (+7.16%)
» More
» Details

Insider Trades

Latest Guru Trades with CDXS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:PETX, NAS:CMRX, XKRX:041910, ROCO:1760, XKRX:011000, NAS:CRIS » details
Traded in other countries:4QK.Germany,
Codexis Inc is a developer of proprietary biocatalysts, which are enzymes or microbes that initiate or accelerate chemical reactions. It has recently started to use its technology to develop biocatalysts for use in the fine chemicals markets.

Codexis Inc was incorporated in Delaware in January 2002. The Company is a developer of proprietary biocatalysts, which are enzymes or microbes that initiate or accelerate chemical reactions. Its proven technologies enable scale-up and implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable process development, from research to manufacturing. The Company has commercialized its technology and products in the pharmaceuticals market. The pharmaceutical customers, which include several pharmaceutical companies, use its technology, products and services in their manufacturing process development, including in the production of some of the world's bestselling and fastest growing drugs. It has recently started to use its technology to develop biocatalysts for use in the fine chemicals markets. The fine chemicals market is similar to its pharmaceutical business and consists of several large market segments, including food, animal feed, polymers, flavors and fragrances and agricultural chemicals, and so it is a natural fit for its technology. Its technology is also currently being used by a customer to manufacture butadiene, an intermediate for the manufacture of polymers. The Company's pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (API), and Codex Biocatalyst Kits and Panels. It markets and sells enzymes, development services and Codex Biocatalyst Kits and Panels screening tools that enable novel manufacturing processes for APIs and their precursor pharmaceutical intermediates. It also markets and sells pharmaceutical intermediates that are manufactured using its custom enzymes. The registered and pending United States and foreign trademarks include Codexis, Codex, CodeEvolver, CodeXporter, CodeXol, CodeXyme, Powered by CodeEvolver, We Are Biocatalysis, Mosaic, Sage, Microcyp, Hit from a Kit, Prosar and a Codexis and design mark. The competitors include Solvias Inc. and Takasago International Corporation who use metal-based chemical reactions for their pharmaceutical products, industrial enzyme companies, such as Novozymes, as well as subsidiaries of larger pharmaceutical companies, such as DSM, Cambrex Corporation and Almac Group Ltd. There is also competition in the customized and optimized enzyme area from several small European companies, such as BRAIN AG, C-LEcta GmbH and evocatal GmbH. The Company's operations comply with environmental laws and regulations.

Ratios

vs
industry
vs
history
Price/Owner Earnings (ttm) 144.66
CDXS's Price/Owner Earnings (ttm) is ranked lower than
84% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 37.01 vs. CDXS: 144.66 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
CDXS' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 112.5  Med: 120.36 Max: 137.5
Current: 144.66
112.5
137.5
P/B 10.33
CDXS's P/B is ranked lower than
83% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. CDXS: 10.33 )
Ranked among companies with meaningful P/B only.
CDXS' s P/B Range Over the Past 10 Years
Min: 0.84  Med: 2.45 Max: 10.33
Current: 10.33
0.84
10.33
P/S 3.80
CDXS's P/S is ranked higher than
80% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 12.41 vs. CDXS: 3.80 )
Ranked among companies with meaningful P/S only.
CDXS' s P/S Range Over the Past 10 Years
Min: 0.39  Med: 1.90 Max: 5.56
Current: 3.8
0.39
5.56
PFCF 72.37
CDXS's PFCF is ranked lower than
76% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 26.95 vs. CDXS: 72.37 )
Ranked among companies with meaningful PFCF only.
CDXS' s PFCF Range Over the Past 10 Years
Min: 56.25  Med: 99999999.99 Max: 99999999.99
Current: 72.37
56.25
99999999.99
POCF 44.51
CDXS's POCF is ranked lower than
68% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. CDXS: 44.51 )
Ranked among companies with meaningful POCF only.
CDXS' s POCF Range Over the Past 10 Years
Min: 34.62  Med: 161.82 Max: 609.5
Current: 44.51
34.62
609.5
Current Ratio 1.75
CDXS's Current Ratio is ranked lower than
79% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. CDXS: 1.75 )
Ranked among companies with meaningful Current Ratio only.
CDXS' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 2.56 Max: 3.98
Current: 1.75
1.14
3.98
Quick Ratio 1.68
CDXS's Quick Ratio is ranked lower than
76% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. CDXS: 1.68 )
Ranked among companies with meaningful Quick Ratio only.
CDXS' s Quick Ratio Range Over the Past 10 Years
Min: 1.07  Med: 2.45 Max: 3.75
Current: 1.68
1.07
3.75
Days Inventory 44.57
CDXS's Days Inventory is ranked higher than
80% of the 446 Companies
in the Global Biotechnology industry.

( Industry Median: 127.50 vs. CDXS: 44.57 )
Ranked among companies with meaningful Days Inventory only.
CDXS' s Days Inventory Range Over the Past 10 Years
Min: 31.91  Med: 54.08 Max: 196.04
Current: 44.57
31.91
196.04
Days Sales Outstanding 36.94
CDXS's Days Sales Outstanding is ranked higher than
71% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 63.27 vs. CDXS: 36.94 )
Ranked among companies with meaningful Days Sales Outstanding only.
CDXS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 31.19  Med: 52.25 Max: 92.67
Current: 36.94
31.19
92.67
Days Payable 136.55
CDXS's Days Payable is ranked higher than
77% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 58.35 vs. CDXS: 136.55 )
Ranked among companies with meaningful Days Payable only.
CDXS' s Days Payable Range Over the Past 10 Years
Min: 43.52  Med: 175.37 Max: 503.44
Current: 136.55
43.52
503.44

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 28.93
CDXS's Price/Net Current Asset Value is ranked lower than
89% of the 783 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. CDXS: 28.93 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CDXS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.19  Med: 4.77 Max: 48.63
Current: 28.93
2.19
48.63
Price/Tangible Book 15.00
CDXS's Price/Tangible Book is ranked lower than
86% of the 949 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. CDXS: 15.00 )
Ranked among companies with meaningful Price/Tangible Book only.
CDXS' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.34  Med: 3.16 Max: 16.7
Current: 15
1.34
16.7
Price/Median PS Value 1.99
CDXS's Price/Median PS Value is ranked lower than
80% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. CDXS: 1.99 )
Ranked among companies with meaningful Price/Median PS Value only.
CDXS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.24  Med: 0.98 Max: 2.64
Current: 1.99
0.24
2.64
Earnings Yield (Greenblatt) (%) -6.42
CDXS's Earnings Yield (Greenblatt) (%) is ranked higher than
55% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. CDXS: -6.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CDXS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -26.2  Med: 0.00 Max: 0
Current: -6.42
-26.2
0

More Statistics

Revenue (TTM) (Mil) $43.00
EPS (TTM) $ -0.23
Beta-1.31
Short Percentage of Float1.82%
52-Week Range $2.93 - 4.72
Shares Outstanding (Mil)40.79

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 48 45 68
EPS ($) -0.20 -0.37 0.07
EPS without NRI ($) -0.20 -0.37 0.07
EPS Growth Rate
(3Y to 5Y Estimate)
15.00%
» More Articles for CDXS

Headlines

Articles On GuruFocus.com
Weekly 3-Year Lows Highlight: SEAS, AMTG, AHH, NCTY, CDXS Dec 30 2013 
Weekly CEO Buys Highlight: AKAM, DRC, MDRX, MTG, CDXS Mar 17 2013 
A New Beginning for Codexis? Mar 08 2013 
Weekly CFO Buys Highlight: ASNB, FXCM, CDXS, VTNC, BRS Sep 24 2012 

More From Other Websites
Codexis to Present at Upcoming Investment Conferences May 18 2016
Codexis to Present at Upcoming Investment Conferences May 18 2016
Codexis, Inc. :CDXS-US: Earnings Analysis: Q1, 2016 By the Numbers May 17 2016
CODEXIS INC Financials May 17 2016
Edited Transcript of CDXS earnings conference call or presentation 9-May-16 8:30pm GMT May 10 2016
Codexis reports 1Q loss May 09 2016
Codexis reports 1Q loss May 09 2016
CODEXIS INC Files SEC form 8-K, Results of Operations and Financial Condition May 09 2016
Codexis Inc Earnings Call scheduled for 4:30 pm ET today May 09 2016
Codexis Reports Financial Results for the First Quarter of 2016 May 09 2016
Codexis Reports Financial Results for the First Quarter of 2016 May 09 2016
Q1 2016 Codexis Inc Earnings Release - After Market Close May 09 2016
Codexis to Hold 2016 First Quarter Conference Call on May 9 May 02 2016
Codexis to Hold 2016 First Quarter Conference Call on May 9 May 02 2016
Codexis Completes CodeEvolver® Technology Transfer to GSK; Earns $7.5 Million Milestone Payment May 02 2016
Codexis Completes CodeEvolver® Technology Transfer to GSK; Earns $7.5 Million Milestone Payment May 02 2016
ETF’s with exposure to Codexis, Inc. : April 20, 2016 Apr 20 2016
ETF’s with exposure to Codexis, Inc. : April 8, 2016 Apr 07 2016
ETF’s with exposure to Codexis, Inc. : March 21, 2016 Mar 21 2016
Codexis, Inc. :CDXS-US: Earnings Analysis: 2015 By the Numbers Mar 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)